Pliant Therapeutics (PLRX) Equity Average (2019 - 2026)

Pliant Therapeutics (PLRX) has 8 years of Equity Average data on file, last reported at $173.2 million in Q1 2026.

• Equity Average for Q1 2026 came in at $173.2 million, down 38.29% year-over-year; the trailing twelve-month figure through Mar 2026 was $173.2 million (down 38.29% YoY), and the FY2025 annual result was $242.6 million, down 37.6% from the prior year.
• Equity Average retreated to $173.2 million in Q1 2026 per PLRX's latest filing, from $190.8 million in the prior quarter.
• Over five years, Equity Average peaked at $547.5 million in Q2 2023 and troughed at $160.8 million in Q2 2022.
• A 5-year average of $327.3 million and a median of $325.0 million in 2024 frame the typical range for Equity Average.
• The sharpest annual moves came in 2023 and 2025: Equity Average jumped 240.5% in 2023, then sank 43.08% in 2025.
• A 5-year view of Equity Average shows it stood at $325.2 million in 2022, then jumped by 50.17% to $488.3 million in 2023, then slumped by 33.45% to $325.0 million in 2024, then tumbled by 41.3% to $190.8 million in 2025, then retreated by 9.21% to $173.2 million in 2026.
• Business Quant data shows PLRX's Equity Average at $173.2 million in Q1 2026, $190.8 million in Q4 2025, and $210.2 million in Q3 2025.